Investor Relations

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for people living with immune-inflammatory diseases.

Press Releases

November 14, 2022
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Read More
September 1, 2022
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Read More

Events & Presentations

More events are coming soon.

Corporate Presentation

presentation
November 24, 2022 4:09 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart